단일 현탁액 세포에서 약물 및 대사 산물의 질량 분석 분석을 위한 단일 프로브와 결합된 통합 셀 조작 플랫폼

Executive Industry Relevance

The integration of single-probe mass spectrometry with a cell manipulation platform enables direct, quantitative analysis of drugs and metabolites in individual suspension cells from patient-derived samples. This approach addresses the challenge of studying cellular heterogeneity and drug response in a near-native environment, supporting predictive confidence in early discovery and translational research. The platform's minimal sample preparation and compatibility with liquid biopsies position it as a valuable asset for risk-adjusted portfolio decisions in disease biology and personalized medicine.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of therapeutic hypotheses by quantifying intracellular drug and metabolite levels in single cells.
• Supports biological de-risking by revealing cellular heterogeneity and functional target engagement in patient-derived samples.
• Facilitates predictive confidence and triage of targets based on direct molecular readouts from disease-relevant cells.

Screening & Assay Development

• Prepares validated single-cell systems for downstream compound screening and mechanistic studies.
• Delivers reproducible, quantitative mass spectrometry outputs for assay standardization and benchmarking.
• Enables scalable, high-content analysis of drug uptake and metabolism at the single-cell level.

Translational & Preclinical Research

• Aligns with translational biomarker strategies by enabling analysis of patient-isolated cells from body fluids.
• Provides continuity from discovery through preclinical validation by supporting liquid biopsy and disease-state profiling.
• De-risks advancement decisions by offering direct evidence of drug action in clinically relevant cell populations.

Pipeline & Workflow Integration

This platform bridges early discovery, lead identification, and translational research by enabling direct, quantitative analysis of single suspension cells from clinical samples.

• Discovery Biology: Supports hypothesis testing and pathway clarification through single-cell drug and metabolite profiling.
• Screening: Provides assay-ready, reproducible systems for evaluating compound effects in heterogeneous cell populations.
• Analytics: Delivers high-resolution, quantitative mass spectrometry data for comparative analysis across conditions.
• Translational Research: Connects discovery outputs to preclinical and clinical biomarker strategies using patient-derived cells.
• Enterprise Reuse: Establishes a reusable analytical capability for diverse disease models and sample types.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and target validation by resolving cellular heterogeneity at the molecular level.
• Operational Value: Streamlines workflows with minimal sample preparation and robust, reproducible outputs.
• Strategic Value: Improves go/no-go decisions and capital efficiency by providing actionable data from clinically relevant samples.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of programs based on direct evidence from patient-derived cells.

Implementation Considerations

• Requires expertise in single-cell manipulation, mass spectrometry, and data interpretation.
• Demands specialized instrumentation, including microinjectors, inverted microscopes, and high-resolution mass spectrometers.
• Necessitates cross-team standardization of sample handling and analytical protocols.
• Adaptable to various cell types and body fluids, but may require optimization for specific disease models.
• Practical limitations include throughput and the need for precise cell selection and transfer.

Biopharma FAQs